Global Panic Disorders Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Panic Disorders Market Segmentation, By Type (Agoraphobia, Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Specific Phobias, Generalized Anxiety Disorder (GAD), and Major Depressive Disorder (MDD)), Therapy and Devices (Electroconvulsive Therapy ECT, and Cognitive-Behavioral Therapy (CBT)), Drug Class (Benzodiazepines (BZD), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Monoamine Oxidase Inhibitors (MAOIs), Anti-Depressants, Tricyclic Antidepressants (TCAs), Pregabalin, Buspirone, and Sertraline), Distribution Channel (Pharmacies, Drug Stores, E-Commerce, Online, and Offline), (Administration Oral, Parenteral, and Others), Treatment (Medication, Beta Blockers, Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Benzodiazepines, Anti-epilepsy, and Others), Dosage (Tablets, Injections, Others), End-User (Hospitals, Mental Healthcare Centres, Asylums, and Others) - Industry Trends and Forecast to 2032

Panic Disorders Market Size

• The global panic disorders market size was valued at USD 10.37 billion in 2024 and is expected to reach USD 14.26 billion by 2032, at a CAGR of 4.06% during the forecast period
• The market growth is largely fueled by the increasing prevalence of mental health concerns globally, particularly anxiety-related conditions, which has driven the demand for effective diagnosis, treatment, and support solutions for panic disorders. Growing societal awareness, coupled with efforts from governments and healthcare organizations, is helping to destigmatize mental health issues, thereby encouraging more individuals to seek medical attention and boosting the overall market growth
• Furthermore, the rising consumer demand for accessible, user-friendly, and integrated mental healthcare services is positioning panic disorder treatments as a primary focus within the psychiatric and behavioral health sector. The growing adoption of telepsychiatry, digital therapeutics, and mobile health applications is enabling broader access to care, making treatment more personalized and convenient. These converging factors are accelerating the uptake of panic disorder therapies and technologies, significantly boosting the industry’s growth trajectory across both developed and emerging economies

Panic Disorders Market Analysis

• Panic Disorder, a type of anxiety disorder characterized by recurrent panic attacks, is witnessing increasing demand for advanced treatment solutions. The market growth is driven by rising prevalence of mental health disorders, greater awareness about early diagnosis, and growing adoption of novel therapies including antidepressants, anti-anxiety drugs, and cognitive behavioral therapy (CBT)
• The growing demand for panic disorder treatment is primarily fueled by rising stress levels globally, increasing healthcare spending on mental health, and the integration of digital health tools such as telepsychiatry and mobile mental health applications, which improve accessibility and patient engagement
• North America dominated the panic disorder market with the largest revenue share of 38.5% in 2024, attributed to a higher prevalence of anxiety disorders, strong healthcare infrastructure, favorable reimbursement policies, and active initiatives by key pharmaceutical players. The U.S. accounted for the majority of the regional revenue, supported by early adoption of innovative therapies and widespread awareness programs
• Asia-Pacific is expected to be the fastest-growing region in the panic disorder market during the forecast period, driven by rising mental health awareness, expanding healthcare infrastructure, and increasing government focus on psychiatric care in countries such as China, India, and Japan
• The CBT segment dominated the panic disorder market with the largest market share of 61.0% in 2024, reflecting its widespread acceptance as a first-line, non-invasive therapeutic approach for panic disorders. CBT is extensively used in outpatient clinics, psychiatric centers, and digital therapy programs

Report Scope and Panic Disorders Market Segmentation     

Panic Disorders Market Trends

Enhanced Accessibility Through Digital Mental Health Solutions

• A significant and accelerating trend in the global panic disorders market is the deepening integration with artificial intelligence (AI) and popular voice-controlled ecosystems. This fusion of technologies is significantly enhancing patient convenience and accessibility to mental health care

  • For instance, several mental health applications and digital therapeutic platforms now integrate seamlessly with leading voice assistants, enabling patients to access guided breathing exercises, mindfulness sessions, or therapy reminders through simple voice commands. Similarly, healthcare providers are utilizing AI-powered chatbots and voice tools to provide discreet and immediate support for individuals experiencing symptoms of panic attacks, thereby improving treatment adherence and engagement

• AI integration in panic disorder management enables features such as real-time monitoring of symptoms, predictive analytics to identify early warning signs, and personalized treatment recommendations. For instance, certain platforms use AI algorithms to analyze patient speech and behavioral patterns, providing intelligent alerts to clinicians when signs of heightened anxiety or panic episodes are detected. Furthermore, voice control capabilities allow patients hands-free access to coping strategies, guided relaxation techniques, or emergency contact features during panic episodes, offering critical support when needed most
• The seamless integration of AI-enabled solutions with broader digital health platforms facilitates centralized management of various aspects of mental health care. Through a single interface, patients can access therapy modules, track their progress, monitor medication schedules, and connect with healthcare providers, thereby creating a unified and holistic treatment experience
• This trend towards more intelligent, intuitive, and interconnected mental health solutions is fundamentally reshaping patient expectations for accessible care. Consequently, companies and healthcare innovators are developing AI-enabled panic disorder management platforms with features such as automated symptom tracking, predictive intervention alerts, and compatibility with leading voice assistants
• The demand for panic disorder solutions that offer seamless AI and voice control integration is growing rapidly across both clinical and consumer health settings, as patients and providers increasingly prioritize convenience, personalization, and comprehensive digital mental health functionality

Panic Disorders Market Dynamics

Driver

Growing Need Due to Rising Prevalence and Increasing Mental Health Awareness

• The increasing prevalence of panic disorder across the globe, coupled with rising awareness regarding mental health conditions, is a significant driver for the heightened demand for diagnostic and therapeutic solutions in this market

  • For instance, in April 2024, several leading research institutions initiated clinical studies focusing on novel biomarker-based diagnostic methods and digital cognitive behavioral therapy (CBT) platforms for panic disorder. Such strategies by key players are expected to drive industry growth during the forecast period

• As patients and healthcare providers become more aware of the importance of early diagnosis and treatment of anxiety-related disorders, the market is witnessing a shift toward evidence-based therapies, including advanced pharmacological interventions and integrated digital health platforms. These offer more effective and accessible solutions compared to traditional care approaches
• Furthermore, the growing popularity of telepsychiatry, mental health apps, and online counseling platforms is making treatment for panic disorder more accessible, offering seamless integration with existing healthcare systems and providing continuous monitoring and support
• The convenience of online therapy sessions, remote access to specialists, and the ability to manage treatment plans through digital health applications are key factors propelling the adoption of panic disorder treatment in both developed and emerging economies. The trend toward destigmatizing mental health care and the increasing availability of user-friendly treatment options further contribute to market growth

Restraint/Challenge

Concerns Regarding Side Effects, Stigma, and High Treatment Costs

• Concerns surrounding the potential side effects of pharmacological treatments for panic disorder, including dependency risks with benzodiazepines and tolerability issues with antidepressants, pose a significant challenge to broader adoption. These limitations make some patients hesitant to begin or continue conventional therapies

  • For instance, high-profile reports of medication overuse and misuse in psychiatric care have raised awareness of these risks, leading to greater scrutiny of pharmacological treatment approaches for panic disorder

• Addressing these challenges through the development of safer drug formulations, expanding access to psychotherapy-based approaches such as CBT, and increasing awareness of non-pharmacological treatments is crucial for building patient trust. Companies and mental health service providers are increasingly emphasizing combined therapy models that balance medication with counseling and digital interventions
• In addition, the relatively high cost of long-term therapy, particularly when advanced treatment options or private psychiatric care are involved, can be a barrier to adoption for patients in low- and middle-income countries or for those without adequate insurance coverage. While online therapy platforms and generic medications have helped reduce costs, comprehensive treatment programs often remain out of reach for price-sensitive populations
• Overcoming these challenges through affordable treatment options, expanded insurance coverage, government mental health initiatives, and widespread consumer education will be vital for sustained growth of the panic disorder treatment market

Panic Disorders Market Scope

The market is segmented on the basis of type, therapy and devices, drug class, distribution channel, administration, treatment, dosage, and end-user.

• By Type

On the basis of type, the panic disorders market is segmented into Agoraphobia, Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Specific Phobias, Generalized Anxiety Disorder (GAD), and Major Depressive Disorder (MDD). The Major Depressive Disorder (MDD) segment dominated the largest market revenue share of 28.5% in 2024, driven by the high global prevalence of depression and its strong comorbidity with panic disorders. The growing mental health awareness, early diagnosis programs, and the availability of effective treatment options have significantly contributed to the market dominance. MDD patients are increasingly accessing both pharmacological and non-pharmacological interventions, which reinforces the adoption trends. The segment benefits from widespread insurance coverage and consistent physician recommendations. Increasing digital mental health initiatives and online therapy programs also support market expansion. In addition, research and clinical trials focusing on depression management strengthen its market position and ensure continued growth.

The Generalized Anxiety Disorder (GAD) segment is expected to witness the fastest growth at a CAGR of 21.0% from 2025 to 2032, owing to rising stress levels, urbanization, and workplace pressures. GAD often requires long-term management, which drives the adoption of both medications and therapy programs. The segment is gaining momentum due to enhanced diagnostic tools, better patient compliance, and targeted awareness campaigns. Technological solutions such as mobile apps for anxiety tracking and teletherapy platforms further accelerate adoption. Research institutions are actively promoting early intervention strategies for GAD. In addition, expanding treatment options and access to mental health specialists contribute to the rapid growth. Governments and NGOs supporting mental well-being campaigns indirectly encourage higher diagnosis rates. This segment is therefore positioned as a key growth driver in the panic disorders market.

• By Therapy and Devices

On the basis of therapy and devices, the Panic Disorders market is segmented into Electroconvulsive Therapy (ECT) and Cognitive-Behavioral Therapy (CBT). The CBT segment held the largest market share of 61.0% in 2024, reflecting its widespread acceptance as a first-line, non-invasive therapeutic approach for panic disorders. CBT is extensively used in outpatient clinics, psychiatric centers, and digital therapy programs. Its evidence-based efficacy, safety, and adaptability to individual patient needs enhance patient compliance. CBT’s integration with telehealth and mobile platforms has broadened its reach, particularly in underserved areas. Awareness campaigns and guidelines by psychiatric associations further support the segment. Insurance reimbursement policies for CBT also boost its adoption. The continued demand for non-pharmacological interventions ensures sustained market dominance for this segment.

The Electroconvulsive Therapy (ECT) segment is projected to witness the fastest CAGR of 17.5% from 2025 to 2032, driven by its proven efficacy in treatment-resistant panic disorders. Modern ECT devices have improved safety and reduced side effects, making the procedure more acceptable to both patients and physicians. Hospitals and specialized mental health facilities are increasingly adopting ECT for severe cases. Ongoing clinical research supports its role in complex and comorbid conditions. Awareness among psychiatrists about patient selection and safety protocols contributes to its adoption. The segment also benefits from institutional support and expanding mental health infrastructure. Patients seeking rapid symptom relief in severe panic cases are accelerating segment growth.

• By Drug Class

On the basis of drug class, the panic disorders market is segmented into Benzodiazepines (BZD), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Monoamine Oxidase Inhibitors (MAOIs), Anti-Depressants, Tricyclic Antidepressants (TCAs), Pregabalin, Buspirone, and Sertraline. The Anti-Depressants segment dominated the largest revenue share of 34.2% in 2024, due to its broad clinical acceptance, effectiveness, and availability in both branded and generic formulations. Physicians frequently prescribe anti-depressants as the mainstay treatment for panic disorders and related comorbid conditions. Patient adherence is high due to established dosing schedules and proven efficacy. Pharmaceutical companies continue to invest in research for newer antidepressant formulations. Reimbursement and insurance coverage make these drugs accessible to a wider patient base. Awareness campaigns highlighting their effectiveness further enhance adoption.

The SNRI segment is expected to witness the fastest CAGR of 19.8% from 2025 to 2032, fueled by their favorable safety profile and reduced risk of dependency compared to benzodiazepines. SNRIs are effective in treating coexisting anxiety and depression, making them highly preferred by clinicians. The growing number of treatment guidelines recommending SNRIs for panic disorders strengthens adoption. Rising patient awareness and preference for safer, long-term treatment options also support market growth. Pharmaceutical innovation continues to introduce new SNRI molecules and combination therapies. Telepsychiatry consultations contribute to improved patient access to SNRIs. Increasing government support for mental health treatments indirectly benefits this segment.

• By Distribution Channel

On the basis of distribution channel, the panic disorders market is segmented into pharmacies, drug stores, E-commerce, online, and offline. The Pharmacies segment held the largest revenue share of 45.5% in 2024, primarily due to easy accessibility, professional counseling, and trusted dispensing practices. Pharmacies act as the first point of contact for patients seeking medications for panic disorders. Urban and semi-urban presence ensures widespread penetration. Strong supply chain infrastructure and brand trust contribute to dominance. Many pharmacies also provide patient education and adherence monitoring, supporting treatment outcomes. Government regulations and healthcare insurance coverage encourage pharmacy utilization. The segment is stable due to habitual patient behavior and routine prescription refills.

The E-Commerce segment is projected to grow at the fastest CAGR of 23.0% from 2025 to 2032, driven by the convenience of online ordering, digital prescription services, and home delivery. Telemedicine and online counseling platforms further increase e-commerce adoption. Rising awareness of self-care and mental health apps encourages online pharmacy usage. E-commerce platforms are expanding product availability to rural areas, where physical access is limited. Partnerships between mental health platforms and online pharmacies improve trust and adoption. Online sales also provide discreet access for patients seeking privacy. Rapid digital penetration globally supports high growth potential for this channel.

• By Administration

On the basis of administration, the panic disorders market is segmented into oral, parenteral, and others. The oral segment dominated the largest share of 52.0% in 2024, as oral medications are convenient, easy to administer, and cost-effective. High patient compliance and broad availability of oral formulations drive adoption. Oral administration is preferred for long-term management of panic disorders and associated comorbidities. Physicians favor oral drugs for outpatient therapy due to ease of monitoring. Patients have greater comfort and reduced stigma with oral administration. Pharmaceutical companies prioritize oral formulations for mass production and marketing. The segment also benefits from insurance coverage and reimbursement schemes, strengthening its dominance.

The Parenteral segment is projected to witness the fastest CAGR of 18.5% from 2025 to 2032, primarily due to its rapid therapeutic effect in severe panic attacks or treatment-resistant cases. Hospitals and specialized mental health centers prefer parenteral therapy for controlled administration. Innovations in prefilled syringes and injectable formulations improve safety and convenience. Clinical evidence supports fast symptom relief with parenteral methods. Increasing institutional adoption and awareness contribute to growth. Acute management scenarios, especially in hospital settings, boost market demand. Expansion of mental health infrastructure also drives the segment.

• By Treatment

On the basis of treatment, the panic disorders market is segmented into medication, beta blockers, serotonin and norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, anti-epilepsy, and others. The Medication segment captured the largest revenue share of 49.5% in 2024, as pharmacological treatment remains the primary approach for managing panic disorders. High adoption is driven by physician preference, availability, and insurance coverage. Medication ensures controlled symptom management and long-term compliance. Growing prevalence of panic disorders globally increases overall prescription volumes. Treatment guidelines and evidence-based recommendations reinforce medication usage. Patients show higher adherence due to structured dosing regimens. Pharmaceutical investments and drug pipeline innovations strengthen market dominance.

Beta blockers are expected to witness the fastest CAGR of 20.2% from 2025 to 2032, due to their ability to manage physiological symptoms of panic attacks such as palpitations and tremors. Off-label use for performance anxiety is contributing to adoption. Physician awareness of symptom-targeted treatment drives prescription growth. Hospitals and mental health centers increasingly use beta blockers as adjunct therapy. Patient preference for rapid relief enhances demand. Rising research in selective beta blocker therapy further supports expansion. Telemedicine consultations and online pharmacies improve access, accelerating growth.

• By Dosage

On the basis of dosage, the panic disorders market is segmented into tablets, injections, and others. The Tablets segment dominated the largest market share of 55.0% in 2024, owing to its ease of administration, cost-effectiveness, and patient adherence. Tablets are highly preferred for daily maintenance therapy and long-term outpatient management, making them a mainstay in psychiatric and general healthcare settings. Physicians favor tablet formulations for flexible dosing and titration, especially in comorbid conditions. Availability in both generic and branded forms ensures broad accessibility across urban and semi-urban areas. Tablets are convenient for patients who travel or manage treatment independently, further enhancing adoption. Digital adherence tools and mobile reminders support regular consumption, contributing to consistent therapeutic outcomes. The segment is projected to maintain dominance with a CAGR of 18.5% from 2025 to 2032, driven by ongoing patient demand and continuous innovation in formulation.

The Injections segment is expected to witness the fastest CAGR of 19.0% from 2025 to 2032, primarily due to rapid onset of action for acute panic attacks and treatment-resistant patients. Hospitals, mental health centers, and emergency care settings prefer injections for controlled, precise dosing. Recent innovations in prefilled syringes and safety devices improve convenience, reduce dosing errors, and enhance patient confidence. Injectable therapy is often used as an adjunct to oral medications for severe cases, boosting adoption in specialized healthcare facilities. Awareness among psychiatrists regarding rapid symptom management supports the growing demand. Institutional adoption, insurance coverage for inpatient procedures, and growing mental health infrastructure are also key drivers.

• By Drug Class

On the basis of drug class, the panic disorders market is segmented into Benzodiazepines (BZD), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Monoamine Oxidase Inhibitors (MAOIs), Anti-Depressants, Tricyclic Antidepressants (TCAs), Pregabalin, Buspirone, and Sertraline. The Anti-Depressants segment dominated the largest revenue share of 34.2% in 2024, owing to their broad clinical acceptance, proven efficacy, and availability in both branded and generic formulations. Anti-depressants are widely prescribed for panic disorders and associated comorbidities, making them a mainstay in psychiatric care. Physicians favor anti-depressants for long-term management due to their consistent therapeutic outcomes and well-established dosing protocols. The segment benefits from high patient adherence, supportive insurance coverage, and extensive research backing. Awareness campaigns and mental health programs further enhance adoption, making anti-depressants the leading treatment option. Pharmaceutical companies continue to innovate and expand formulations, strengthening their market position. The segment is projected to maintain dominance with a CAGR of 18.0% from 2025 to 2032, driven by ongoing demand and clinical preference.

The SNRI segment is expected to witness the fastest CAGR of 19.8% from 2025 to 2032, primarily due to its favorable safety profile, reduced dependency risk, and efficacy in treating comorbid anxiety and depression. SNRIs are increasingly preferred by clinicians for patients requiring long-term therapy and symptom stabilization. Growing awareness of safer treatment alternatives and patient preference for non-benzodiazepine options boost adoption. Clinical guidelines recommending SNRIs as first-line therapy for panic disorders strengthen market uptake. Pharmaceutical innovation, new SNRI molecules, and combination therapies further accelerate growth. Telepsychiatry and online prescription services are expanding patient access. The segment’s rapid growth is supported by increasing digital health integration, institutional adoption, and government support for mental health programs, making SNRIs a key driver of the panic disorders market.

Panic Disorders Market Regional Analysis

• North America dominated the panic disorders market with the largest revenue share of 38.5% in 2024, attributed to the higher prevalence of anxiety and panic-related conditions, strong healthcare infrastructure, favorable reimbursement frameworks, and active initiatives by key pharmaceutical companies
• The region benefits from widespread access to advanced treatment options, including cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and novel digital therapeutics
• The growing focus on mental health awareness campaigns, supported by both government and non-government organizations, continues to drive diagnosis and treatment rates across the region

U.S. Panic Disorders Market Insight

The U.S. panic disorders market captured the largest revenue share of North America in 2024, driven by early adoption of innovative therapies, widespread awareness programs, and strong insurance coverage for psychiatric care. Increasing investments in telepsychiatry platforms and digital CBT applications are expanding patient access to treatment, particularly in rural areas. Pharmaceutical players are actively investing in research and development of next-generation medications with improved efficacy and safety profiles, further fueling growth. The U.S. market is also supported by a robust clinical trial ecosystem and patient advocacy organizations working to destigmatize panic disorder and related conditions.

Europe Panic Disorders Market Insight

The Europe panic disorders market is projected to grow at a notable CAGR throughout the forecast period, supported by stringent mental health policies, increasing government funding for psychiatric services, and the integration of digital health solutions. Rising awareness campaigns by healthcare organizations are driving earlier diagnosis and treatment adoption across the region. European countries are witnessing growing acceptance of telehealth platforms, which are making psychotherapy and counseling services more accessible. The demand for holistic treatment approaches that combine pharmacotherapy with lifestyle-based interventions is also shaping market expansion.

U.K. Panic Disorders Market Insight

The U.K. panic disorders market is anticipated to grow significantly during the forecast period, supported by the National Health Service (NHS) initiatives promoting mental health care accessibility and the rapid integration of online therapy platforms. Growing concerns about anxiety-related conditions in both younger and older populations are driving the adoption of therapy-based and medication-based treatments. In addition, the U.K.’s emphasis on destigmatizing mental health and expanding access to affordable care is expected to stimulate further growth in the market.

Germany Panic Disorders Market Insight

The Germany panic disorders market is expected to expand at a considerable CAGR during the forecast period, driven by the country’s robust healthcare infrastructure, focus on innovation, and rising patient awareness of mental health. Germany’s emphasis on digital health adoption has accelerated the use of telepsychiatry and mental health applications, making treatments more accessible. The market is also being propelled by government-supported initiatives to improve access to mental health services and reduce stigma, with growing adoption of both traditional and digital therapies.

Asia-Pacific Panic Disorders Market Insight

The Asia-Pacific panic disorders market is poised to grow at the fastest CAGR of 24% during the forecast period of 2025 to 2032, driven by rising mental health awareness, expanding healthcare infrastructure, and increasing government focus on psychiatric care in countries such as China, India, and Japan. The region’s rapid urbanization, growing middle-class population, and expanding availability of affordable healthcare solutions are boosting adoption of panic disorder treatments. Government-backed mental health programs and public campaigns are playing a crucial role in addressing stigma and encouraging patients to seek medical help, supporting robust regional growth.

Japan Panic Disorders Market Insight

The Japan panic disorders market is gaining momentum due to the country’s growing recognition of anxiety disorders, rapid urbanization, and strong integration of technology into healthcare delivery. Digital therapy tools, mobile applications, and AI-powered mental health platforms are being widely adopted to provide more accessible and convenient treatment options. Moreover, Japan’s aging population is contributing to higher demand for psychiatric services, as older adults face greater risks of anxiety and panic-related conditions. Government health programs promoting mental well-being further support the market’s expansion.

China Panic Disorders Market Insight

The China panic disorders market accounted for the largest revenue share in Asia-Pacific in 2024, supported by the country’s expanding healthcare infrastructure, rising middle-class population, and growing focus on mental health. Increasing government investment in psychiatric care, coupled with public awareness campaigns aimed at reducing stigma, is driving patient uptake of therapies for panic disorder. Furthermore, China’s growing role as a hub for pharmaceutical manufacturing and digital health solutions is expanding the availability and affordability of treatments, thereby strengthening its market position.

Panic Disorders Market Share

The panic disorders industry is primarily led by well-established companies, including:

• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• AstraZeneca (U.K.)
• Abbott (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Lilly USA, LLC (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GSK plc (U.K.)
• Pfizer Inc. (U.S.)
• Shionogi & Co., Ltd. (Japan)
• Sumitomo Pharma Co., Ltd. (Japan)
• Boehringer Ingelheim International GmbH (Germany)
• H. Lundbeck A/S (Denmark)
• Sanofi (France)
• Neurocrine Biosciences, Inc. (U.S.)

Latest Developments in Global Panic Disorders Market

• In September 2024, Big Health announced that the U.S. Food and Drug Administration (FDA) granted clearance to its prescription digital therapeutic, DaylightRx, for the treatment of generalized anxiety disorder (GAD). This marked the first FDA-cleared non-drug treatment for GAD, offering patients an alternative to traditional pharmacological therapies
• In May 2025, researchers from the Norwegian University of Science and Technology published a study in BMC Psychiatry evaluating the long-term effectiveness of the Bergen 4-Day Treatment (B4DT) for patients with panic disorder, with or without agoraphobia. The study demonstrated sustained improvements in panic disorder symptoms, depression, and generalized anxiety, highlighting B4DT's potential as an effective treatment option
• In March 2025, Dartmouth researchers conducted the first-ever clinical trial of a generative AI-powered therapy chatbot, Therabot, for mental health treatment. The study found that Therabot resulted in significant improvements in participants' symptoms, marking a promising development in AI-driven mental health interventions
• In May 2025, the FDA granted clearance to Freespira's at-home treatment device for adolescents aged 13–17. This clinically validated, medication-free treatment combines capnometry-guided respiratory intervention with behavioral coaching, offering a new approach to managing panic disorder and post-traumatic stress disorder (PTSD) symptoms in teens

SKU-60547